Brad Prosek

Brad Prosek, Constellation Pharmaceutical’s chief business officer, joined the company in 2017 from All Terrain bioPartners LLC, where he advised and supported a global set of life sciences clients on transaction, corporate and commercial strategy as well as execution. Previously, Brad spent 10 years at Cubist Pharmaceuticals, where he built the company’s market access strategy and organization, led transaction teams responsible for deals, including the acquisition of Trius Therapeutics, supporting the company’s pipeline growth and led a new corporate venture building a complementary infection prevention business. Prior to Cubist, Mr. Prosek served in growing commercial operations and market / business development roles at Biogen, and worked as a health economics and reimbursement strategy consultant with Covance in the United States and Europe.